InnoCare Pharma and Keymed Biosciences Initiate Clinical Trial for ICP-B02 with First Subcutaneous Injection
InnoCare Pharma (HKG: 9969; SHA: 688428) and Keymed Biosciences Inc., (HKG: 2162) have announced a...
HKG: 9969
InnoCare Pharma’s Orelabrutinib Gains NMPA Approval for Recurrent/Refractory MZL Treatment
China-based InnoCare Pharma (HKG: 9969, SHA: 688428) has announced receiving another indication approval from the...
InnoCare Pharma Initiates Clinical Study for BCL2 Inhibitor ICP-248 in China
China-based InnoCare Pharma (HKG: 9969, SHA: 688428) has announced the first subject dosing in a...
InnoCare Pharma Initiates Clinical Study for BCL2 Inhibitor ICP-248 in China
China-based InnoCare Pharma (HKG: 9969, SHA: 688428) has announced the first subject dosing in a...
InnoCare and Keymed Announce First Dosing of ICP-B05 Clinical Study
China-based firms InnoCare Pharma (HKG: 9969, SHA: 688428) and Keymed Biosciences (HKG: 2162) have jointly...
InnoCare Regains Rights to Orelabrutinib as Biogen Terminates Licensing Agreement
Beijing InnoCare Pharma Tech Co., (HKG: 9969), a China-based biotech focusing on cancer and autoimmune...
InnoCare’s Gunagratinib Shows Promising Data in Cholangiocarcinoma at ASCO-GI 2023
Beijing InnoCare Pharma Tech Co. (HKG: 9969), a China-based biotech specializing in cancer and autoimmune...
InnoCare Pharma Receives Hong Kong Approval for Tafasitamab in DLBCL
China-based biopharma InnoCare Pharma (HKG: 9969, SHA: 688428) has announced receiving market approval from the...
InnoCare Pharma’s Orelabrutinib Placed on Partial Clinical Hold by FDA
China-based InnoCare Pharma (HKG: 9969, SHA: 688428) has announced that the US FDA has placed...
InnoCare Receives CDE Approval for Phase II Trial of Orelabrutinib Combination
China-based biopharma InnoCare Pharma (HKG: 9969, SHA: 688428) has announced receiving approval from China’s Center...
InnoCare Pharma’s Hibruka Receives HSA Approval for Mantle Cell Lymphoma in Singapore
China-based InnoCare Pharma (HKG: 9969, SHA: 688428) has announced receiving market approval from the Health...
InnoCare Pharma’s IPO Raises $411M for Drug R&D and Platform Upgrade
China-based InnoCare Pharma (HKG: 9969) has completed an initial public offering (IPO) of 265 million...
InnoCare Pharma’s BCL2 Inhibitor ICP-248 Gains NMPA Approval for Clinical Study
China’s Beijing InnoCare Pharma (HKG: 9969) announced that it has received approval from the National...
InnoCare Pharma and CStone Pharmaceuticals’ Drugs Receive Prioritized CDE Review
The Center for Drug Evaluation (CDE) has granted prioritized review status to InnoCare Pharma’s (HKG:...
InnoCare Pharma Files for STAR Market IPO to Raise RMB 4B for Drug R&D
China-based InnoCare Pharma (HKG: 9969) has filed for an initial public offering (IPO) on the...
InnoCare Pharma’s 2022 Interim Report Shows Strong Revenue Growth Driven by Orelabrutinib Sales
China-based InnoCare Pharma (HKG: 9969) announced its 2022 interim financial results, reporting total revenues of...
InnoCare Pharma’s Orelabrutinib sNDA Accepted for Marginal Zone Lymphoma
InnoCare Pharma (HKG: 9969) announced that a supplemental New Drug Application (sNDA) for its Bruton’s...
InnoCare Pharma Doses First Patient in ICP-488 Study for Autoimmune Diseases
China-based InnoCare Pharma (HKG: 9969) announced that the first subject has been dosed in a...
InnoCare’s Tafasitamab Receives First Prescription in China’s Bo’Ao Lecheng Pilot Zone
China-based InnoCare (HKG: 9969) announced that the first prescription for its pipeline candidate tafasitamab (trade...
InnoCare Pharma’s BCL2 Inhibitor ICP-248 Accepted for NMPA Review
China’s Beijing InnoCare Pharma (HKG: 9969) announced that an investigational new drug (IND) filing for...